Article
Dentistry, Oral Surgery & Medicine
Yu-Yue Zhao, Jun-Xiang Lian, Zhou Lan, Ke-Long Zou, Wei-Ming Wang, Guang-Tao Yu
Summary: This study found that ferroptosis can reverse the immunosuppressive tumor microenvironment and promote anti-tumor immune response. High expression of GPX4 was associated with poor survival, while the expression of GPX4 was negatively correlated with calreticulin, a protein related to immunogenic cell death.
Article
Cell Biology
Xin Tang, Dongfang Guo, Xi Yang, Rui Chen, Qingming Jiang, Zhen Zeng, Yu Li, Zhenyu Li
Summary: This study identified the ICD gene signature in HGGs and its potential implications for predicting the responsiveness to ICB immune therapy and patient outcomes.
Review
Oncology
Kaikai Wang, Junjie Wang, Jiahao Zhang, Anke Zhang, Yibo Liu, Jingyi Zhou, Xiaoyu Wang, Jianmin Zhang
Summary: Glioma, the most common intracranial malignant tumor in adults, has a poor prognosis with a low 5-year survival rate. Immunotherapy, which shows great potential in various tumor treatments, is limited in treating glioma due to the immunosuppressive microenvironment induced by the tumor. Remodeling the immunosuppressive microenvironment is considered a practical approach to overcome immunotherapy resistance. Recent studies have highlighted the role of ferroptosis, a new form of cell death, in glioma progression and the immune microenvironment, creating interest in the crosstalk between ferroptosis and the tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Desheng Qi, Milin Peng
Summary: Cell death is a common biological process in various physiological and pathological conditions. There are multiple types of cell death, including apoptosis and the newly discovered ferroptosis. Ferroptosis has been found to have potential antitumor effects and may also impact immune cells in the tumor microenvironment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Qing Bi, Ze-jia Sun, Ji-yue Wu, Wei Wang
Summary: This review introduces the mechanisms of ferroptosis, discusses the crosstalk between ferroptosis and cancer, demonstrates the potential ways in which ferroptosis shapes the pro-tumor immune microenvironment, and presents thoughts on ferroptosis-based cancer therapies.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Robin Demuynck, Iuliia Efimova, Faye Naessens, Dmitri Krysko
Summary: Ferroptosis is a newly discovered form of regulated cell death distinct from apoptosis and necroptosis, and has potential in anticancer therapy. However, ferroptotic cancer cells may pose a risk of tumor evasion due to decreased phagocytosis and antigen cross-presentation. Factors such as lactate, acidification, and hypoxia in the tumor microenvironment play a role in promoting ferroptosis resistance and affecting its immunogenicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Gastroenterology & Hepatology
Jacinth Wing-Sum Cheu, Derek Lee, Qidong Li, Chi Ching Goh, Macus Hao-Ran Bao, Vincent Wai-Hin Yuen, Misty Shuo Zhang, Chunxue Yang, Cerise Yuen-Ki Chan, Aki Pui-Wah Tse, Grace Fu-Wan Sit, Cindy Xinqi Liu, Irene Oi-Lin Ng, Chun-Ming Wong, Carmen Chak-Lui Wong
Summary: This study identified FSP1 as a potential therapeutic target for hepatocellular carcinoma (HCC). Inhibiting FSP1 induced ferroptosis, enhanced the anti-tumor immune response, and effectively suppressed HCC tumor growth. FSP1 inhibition represents a new therapeutic strategy for HCC.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Immunology
Yirui Kuang, Bincan Jiang, Hecheng Zhu, Yi Zhou, Haoxuan Huang, Can Li, Wenlong Zhang, Xuewen Li, Yudong Cao
Summary: We identified ICD-related genes and divided glioma patients into two subtypes based on gene expression profiles. The high ICD subtype showed worse prognosis, higher immune infiltration, and more active immune response. We also developed a prognostic signature and confirmed the importance of EIF2AK3 gene in glioma.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Sihui Yu, Hongyang Xiao, Li Ma, Jiawen Zhang, Jiarong Zhang
Summary: Immunogenic cell death (ICD) is a revolutionary modality in cancer treatment that can kill primary tumors and prevent recurrence. It involves the production of damage-associated molecular patterns (DAMPs) that can be recognized by pattern recognition receptors (PRRs), leading to infiltration of effector T cells and enhancement of anti-tumor immune responses. Various treatment methods, such as chemo- and radio-therapy, phototherapy, and nanotechnology, can induce ICD and convert dead cancer cells into vaccines. However, the effectiveness of ICD-induced therapies is limited by low accumulation in tumor sites and damage to normal tissues. Novel materials and strategies are being developed to overcome these challenges.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Review
Immunology
Songxin Zhu, Yuming Wang, Jun Tang, Min Cao
Summary: This review investigates the impact of radiotherapy on the tumor immune microenvironment (TIME) and the potential of remodeling TIME to enhance the effectiveness of immunotherapy. Understanding the causes of immune escape in tumor cells is crucial for the treatment of drug-resistant tumors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Yonghua Cai, Ke Li, Jie Lin, Xianqiu Liang, Wei Xu, Zhengming Zhan, Shuaishuai Xue, Yu Zeng, Peng Chai, Yangqi Mao, Zibin Song, Lei Han, Ye Song, Xian Zhang, Hai Wang
Summary: This study explores the role of pyroptosis in glioma and identifies three pyroptosis subtypes with different prognoses. It also finds that patients with high gasdermin-related prognostic index (GPI) are more sensitive to certain treatments. Gasdermin D is identified as a potential biomarker in pyroptosis-inducible therapy combined with immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Shiyang Wu, Dan Liu, Wenpan Li, Baohui Song, Chunlin Chen, Dawei Chen, Haiyang Hu
Summary: Tumor-associated fibroblasts play a crucial role in tumor progression and response to therapy in the immunosuppressive tumor microenvironment. By delivering silybin using nano liposomes, the study successfully altered the tumor immune microenvironment and enhanced the anti-tumor immune response. Combining an immunogenic cell death inducer, liposomal doxorubicin, further improved treatment efficacy and prolonged survival duration.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Oncology
Tianqi Liu, Chen Zhu, Xin Chen, Gefei Guan, Cunyi Zou, Shuai Shen, Jianqi Wu, Yuhang Wang, Zhiguo Lin, Ling Chen, Peng Cheng, Wen Cheng, Anhua Wu
Summary: This study reveals the importance of ferroptosis in glioma and proposes a novel immunotherapeutic strategy that combines immune checkpoint blockade treatment with ferroptosis inhibition, showing a synergistic therapeutic effect.
Review
Biochemistry & Molecular Biology
Izadora de Souza, Maria Carolina Clares Ramalho, Camila Banca Guedes, Isabeli Yumi Araujo Osawa, Linda Karolynne Seregni Monteiro, Luciana Rodrigues Gomes, Clarissa Ribeiro Reily Rocha
Summary: Glioblastoma multiforme is a lethal disease characterized by drug resistance and evasion of cell death. Ferroptosis, a recently described type of cell death, holds potential as a promising approach for glioblastoma treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Yang Liu, Rui Niu, Ruiping Deng, Shuyan Song, Yinghui Wang, Hongjie Zhang
Summary: Immunotherapy is a promising treatment strategy for tumor regression, but it has low response rates due to the lack of immunogenicity in tumor cells. This study presents a strategy to enhance the immunogenicity of tumor cells by inducing cascade immunogenic tumor ferroptosis. A nanoplatform was developed to trigger lipid peroxidation and activate ACSL4, resulting in irreversible cascade immunogenic ferroptosis. This approach could overcome the limitations of current immunotherapy.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
(2023)
